Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Glycoprotein nonmetastatic melanoma protein B (GPNMB) has been demonstrated to mediate pathogenicity in Parkinson's disease (PD) through interactions with α-synuclein, and plasma GPNMB tended to be a novel biomarker for PD.
Objective: The goal of this study was to investigate whether plasma GPNMB could act as a potential biomarker for the clinical diagnosis and severity monitoring of multiple system atrophy (MSA), another typical synucleinopathy.
Methods: Plasma GPNMB levels in patients with MSA, patients with PD, and healthy control subjects (HCs) were quantified using enzyme-linked immunosorbent assays.
Results: A total of 204 patients with MSA, 65 patients with PD, and 207 HCs were enrolled. The plasma GPNMB levels in patients with MSA were similar to those in HCs (P = 0.251) but were significantly lower than those in patients with PD (P = 0.003). Moreover, there was no significant correlation detected between the plasma GPNMB levels and disease severity scores of patients with MSA.
Conclusions: No evidence was detected for the biomarker potential of plasma GPNMB in MSA. © 2023 International Parkinson and Movement Disorder Society.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.29566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased plasma GPNMB levels in patients with parkinson's disease and cognitive impairment.
Sci Rep
July 2025
Department of Neurology, Zhengzhou University People's Hospital, No.7, Wei Wu Road, Jinshui District, Zhengzhou City, 450003, Henan Province, China.
Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a glycosylated type I transmembrane protein that forms soluble GPNMB upon maturation. This study aimed to explore the relationship between plasma GPNMB levels in patients with Parkinson's disease (PD) and their clinical manifestations, as well as their correlations with specific brain regions identified through imaging analysis. This study included patients with PD and healthy control subjects whose plasma GPNMB levels measured by enzyme-linked immunosorbent assay (ELISA).
View Article and Find Full Text PDFSkeletal muscle biomarkers of amyotrophic lateral sclerosis: a large-scale, multi-cohort proteomic study.
medRxiv
April 2025
Department of Neurology and ALS Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Biomarkers with clear contexts-of-use are important tools for ALS therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response. To this end, we undertook a large-scale proteomic study in well-phenotyped cohorts to identify biomarker candidates of ALS disease state and disease progression.
View Article and Find Full Text PDFAcquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade.
Commun Med (Lond)
March 2025
Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Background: Acquired resistance (AR) is a major limitation of immune checkpoint inhibitor (ICI) therapy when treating renal cell carcinoma (RCC). Understanding who will get AR is currently unknown. We hypothesized the T-cell-inhibitory glycoprotein non-metastatic melanoma protein B (GPNMB) to be a prognostic marker for patients with AR.
View Article and Find Full Text PDFProteome-Wide Association Study for Finding Druggable Targets in Progression and Onset of Parkinson's Disease.
CNS Neurosci Ther
February 2025
Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
Objective: To identify and validate causal protein targets that may serve as potential therapeutic interventions for both the onset and progression of Parkinson's disease (PD) through integrative proteomic and genetic analyses.
Method: We utilized large-scale plasma and brain protein quantitative trait loci (pQTL) datasets from the deCODE Health study and the Religious Orders Study/Rush Memory and Aging Project (ROS/MAP), respectively. Proteome-wide association studies (PWAS) were conducted using the OTTERS framework for plasma proteins and the FUSION tool for brain proteins, examining associations with PD onset and three progression phenotypes: composite, motor, and cognitive.
CSF GPNMB in Parkinson's disease: A potential association with age and microglial activation.
J Parkinsons Dis
November 2024
Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Background: Recent evidence suggests a link between glycoprotein non-metastatic melanoma protein B (GPNMB) and Parkinson's disease (PD) pathogenesis. Although elevated plasma GPNMB levels associated with disease severity have been reported in PD, cerebrospinal fluid (CSF) alterations remain elusive.
Objective: To explore CSF GPNMB alterations and its clinical significance in PD.